日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase Ia study to evaluate RO7497987, a FLT3L-fragment Fc fusion protein, in healthy volunteers

在健康志愿者中评估 FLT3L 片段 Fc 融合蛋白 RO7497987 的 Ia 期研究

Iacovelli, Anthony J; Sanjabi, Shomyseh; Monemi, Sharareh; Amitai, Assaf; Decalf, Jérémie; Moussion, Christine; Liao, Michael Z; Rao, Gautham K; Getz, Jennifer; Mancuso, Michael R

Intratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1(+) cDC1 infiltration and activates anti-tumor immunity

肿瘤内递送FLT3L及其CXCR3/CCR5配体可促进XCR1(+) cDC1浸润并激活抗肿瘤免疫。

Gorline, Louise; do Carmo, Fillipe Luiz Rosa; Bourdely, Pierre; Bornères, Jérémie; Vaudiau, Nathan; Semervil, Aurélie; Vetillard, Mathias; Coulibaly, Aboubacar Sidiki K; Jugniot, Natacha; Ok, Agathe; Bausart, Mathilde; Fiquet, Oriane; Andrade, Marine; Fardol, Dicken; Haddar, Ikrame; Abou Nader, Zeina; Weber, Judith; Theobald, Hannah; Collin, Matthieu; Calmette, Joseph; Anselmi, Giorgio; Fico, Flavia; Ginhoux, Florent; Majlessi, Laleh; Gautier, Emmanuel L; Saveanu, Loredana; Helft, Julie; Dalod, Marc; Dusseaux, Mathilde; Di Santo, James P; Hugues, Stéphanie; Guermonprez, Pierre

FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia

基于FLT3L的药物偶联物可有效靶向急性髓系白血病中的化疗耐药性白血病干细胞。

Dengyang Zhang ,Yao Guo ,Zhiyong Peng ,Yan Xiao ,Zhiguang Chang ,Liuting Yu ,Yuming Zhao ,Qi Zhang ,Lingling Ma ,Shuping Li ,Chi-Kong Li ,Kam Tong Leung ,Zhizhuang Joe Zhao ,Chun Chen ,Yun Chen

Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations

无效应分子Fc融合蛋白可改善FLT3L的类药特性,用于癌症免疫疗法组合。

Jérémie Decalf ,Evangeline Toy ,Dongping He ,Radhika Kenkre ,Amy M Berkley ,Devon Wong ,Mandy Kwong ,Yee-Seir Kee ,Yue Sun ,Srividya Myneni ,Xiangdan Wang ,Ahmad Ebtikar ,Anthony Ancheta ,Yanli Yang ,Hok Seon Kim ,Nga Tang ,Debarko Banerji ,Elaine Mai ,Pranay Dogra ,Meredith McLerie ,Alan G Gutierrez ,Geraldine Strasser ,Gautham K Rao ,Matt Betzenhauser ,Wilson Phung ,Peter Day ,Wendy Sandoval ,Ayse Meric Ovacik ,Pamela Chan ,Shomyseh Sanjabi ,Laetitia Comps-Agrar ,Sivan Cohen ,James A Ernst ,Greg A Lazar ,Christopher C Kemball ,Iraj Hosseini ,Yichin Liu ,Jill M Schartner ,Travis W Bainbridge ,Christine Moussion

IL-2/IL-15 signaling induces NK cell production of FLT3LG augmenting anti-PD-1 immunotherapy

IL-2/IL-15信号通路诱导NK细胞产生FLT3LG,从而增强抗PD-1免疫疗法的疗效。

Shayan C Avanessian ,Renske J E van den Bijgaart ,Nayvin W Chew ,Valentina M Supper ,Thao T Tang ,Yuzheng Zhang ,Ying-Qi Zhao ,Kokoro Abe ,Jordan Gauthier ,Kevin C Barry

FLT3L combined with GM-CSF induced dendritic cells drive broad tumor-specific CD8+ T cell responses and remodel the tumor microenvironment to enhance anti-tumor efficacy

FLT3L 与 GM-CSF 诱导的树突状细胞联合作用,可驱动广泛的肿瘤特异性 CD8+ T 细胞反应,并重塑肿瘤微环境,从而增强抗肿瘤疗效。

Qian Zheng # ,Jiajie Zhang # ,He Sui ,Yu Sun ,Ningning Lv ,Lin Liu ,Ming Qu ,Jiateng Tan ,Bin Zhang ,Zhanhao Mo

Erratum: Engineered oncolytic virus OH2-FLT3L enhances antitumor immunity via dendritic cell activation

更正:工程化溶瘤病毒OH2-FLT3L通过激活树突状细胞增强抗肿瘤免疫力

Wan, Duo; Zhang, Qi; Yang, Zhenrong; Zhang, Xiaoli; Xie, Peipei; Cheng, Shujun; Xu, Libin; Liu, Binlei; Zhang, Kaitai; Zhang, Wen

Oncolytic HSV-1 expressing FLT3L kills melanoma, glioblastoma, and pancreatic cancer cells in vitro and induces immunogenic cell death

表达FLT3L的溶瘤性HSV-1在体外可杀死黑色素瘤、胶质母细胞瘤和胰腺癌细胞,并诱导免疫原性细胞死亡

Tuyaerts, Sandra; Geeraerts, Xenia; Reale, Alberto; Stevens, Latoya; Bertazzon, Giada; Brons, Jack; Janssen, Toon; Van Riet, Ivan; Calistri, Arianna; Neyns, Bart

Engineered oncolytic virus OH2-FLT3L enhances antitumor immunity via dendritic cell activation

经基因工程改造的溶瘤病毒OH2-FLT3L通过激活树突状细胞增强抗肿瘤免疫力。

Duo Wan,Qi Zhang,Zhenrong Yang,Xiaoli Zhang,Peipei Xie,Shujun Cheng,Libin Xu,Binlei Liu,Kaitai Zhang,Wen Zhang

FLT3LG as an inflammatory hub bridging tumor immune surveillance to therapy response in breast cancer

FLT3LG作为炎症枢纽,在乳腺癌中连接肿瘤免疫监视和治疗反应

Lu, Yun; Li, Xiangyu; Chao, Tengfei; Xiong, Huihua; Yao, Wei